ZA200507159B - Treatment of intestinal conditions with N-2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine - Google Patents
Treatment of intestinal conditions with N-2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine Download PDFInfo
- Publication number
- ZA200507159B ZA200507159B ZA200507159A ZA200507159A ZA200507159B ZA 200507159 B ZA200507159 B ZA 200507159B ZA 200507159 A ZA200507159 A ZA 200507159A ZA 200507159 A ZA200507159 A ZA 200507159A ZA 200507159 B ZA200507159 B ZA 200507159B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutically acceptable
- heptan
- amine
- tetramethylbicyclo
- hours
- Prior art date
Links
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 title claims abstract description 131
- 230000000968 intestinal effect Effects 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 156
- 238000009472 formulation Methods 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 66
- 230000005176 gastrointestinal motility Effects 0.000 claims abstract description 45
- 230000002159 abnormal effect Effects 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims description 65
- 230000036470 plasma concentration Effects 0.000 claims description 45
- -1 antispasmodics Substances 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 21
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 12
- 208000004998 Abdominal Pain Diseases 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 238000013265 extended release Methods 0.000 claims description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 7
- 229940123859 Nicotinic receptor antagonist Drugs 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 239000003457 ganglion blocking agent Substances 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 5
- 208000002881 Colic Diseases 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 208000009546 Neurogenic bowel Diseases 0.000 claims description 5
- 208000005392 Spasm Diseases 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 208000007784 diverticulitis Diseases 0.000 claims description 5
- 208000001848 dysentery Diseases 0.000 claims description 5
- 208000010227 enterocolitis Diseases 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 5
- 229960001428 mercaptopurine Drugs 0.000 claims description 5
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004963 mesalazine Drugs 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 5
- 230000001272 neurogenic effect Effects 0.000 claims description 5
- 229960002715 nicotine Drugs 0.000 claims description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
- 229940116176 remicade Drugs 0.000 claims description 5
- 230000001148 spastic effect Effects 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 8
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 8
- 235000021323 fish oil Nutrition 0.000 claims 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 8
- 239000012530 fluid Substances 0.000 claims 7
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 4
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 claims 4
- 229930003347 Atropine Natural products 0.000 claims 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 4
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 4
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 4
- 229960005129 alosetron hydrochloride Drugs 0.000 claims 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 4
- 229960003805 amantadine Drugs 0.000 claims 4
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 4
- 229960002576 amiloride Drugs 0.000 claims 4
- 229940069428 antacid Drugs 0.000 claims 4
- 239000003159 antacid agent Substances 0.000 claims 4
- 230000001142 anti-diarrhea Effects 0.000 claims 4
- 229940124425 anti-infective immunomodulator Drugs 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 230000002921 anti-spasmodic effect Effects 0.000 claims 4
- 229940125714 antidiarrheal agent Drugs 0.000 claims 4
- 239000003793 antidiarrheal agent Substances 0.000 claims 4
- 229940125715 antihistaminic agent Drugs 0.000 claims 4
- 239000000739 antihistaminic agent Substances 0.000 claims 4
- 229960005475 antiinfective agent Drugs 0.000 claims 4
- 229940124575 antispasmodic agent Drugs 0.000 claims 4
- 229960001862 atracurium Drugs 0.000 claims 4
- 229960000396 atropine Drugs 0.000 claims 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 4
- 229960002170 azathioprine Drugs 0.000 claims 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- 229910052797 bismuth Inorganic materials 0.000 claims 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 4
- 229960003405 ciprofloxacin Drugs 0.000 claims 4
- 229960004126 codeine Drugs 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- 229960001334 corticosteroids Drugs 0.000 claims 4
- 229960004544 cortisone Drugs 0.000 claims 4
- 229950000405 decamethonium Drugs 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 claims 4
- 229960005493 difenoxin Drugs 0.000 claims 4
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 4
- 229960000920 dihydrocodeine Drugs 0.000 claims 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 4
- 239000002934 diuretic Substances 0.000 claims 4
- 229940030606 diuretics Drugs 0.000 claims 4
- 229960004428 doxacurium Drugs 0.000 claims 4
- BDIVMECULLJBMU-KSSFIOAISA-N erysodine Chemical compound OC1=C(OC)C=C2[C@]34C[C@@H](OC)C=CC3=CCN4CCC2=C1 BDIVMECULLJBMU-KSSFIOAISA-N 0.000 claims 4
- BDIVMECULLJBMU-UHFFFAOYSA-N erysodine Natural products OC1=C(OC)C=C2C34CC(OC)C=CC3=CCN4CCC2=C1 BDIVMECULLJBMU-UHFFFAOYSA-N 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 4
- 229960002428 fentanyl Drugs 0.000 claims 4
- 229960002714 fluticasone Drugs 0.000 claims 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- 229960003883 furosemide Drugs 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 229950002932 hexamethonium Drugs 0.000 claims 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 4
- 229960000890 hydrocortisone Drugs 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 4
- 229960001571 loperamide Drugs 0.000 claims 4
- GBLRQXKSCRCLBZ-IYQFLEDGSA-N meso-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@@H]2[N@@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)[C@@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-IYQFLEDGSA-N 0.000 claims 4
- 229960000282 metronidazole Drugs 0.000 claims 4
- 229960005181 morphine Drugs 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 229960001783 nicardipine Drugs 0.000 claims 4
- 229940127240 opiate Drugs 0.000 claims 4
- 229940105606 oxycontin Drugs 0.000 claims 4
- 229960005118 oxymorphone Drugs 0.000 claims 4
- 229960005457 pancuronium Drugs 0.000 claims 4
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims 4
- 229960005205 prednisolone Drugs 0.000 claims 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 4
- 229960004618 prednisone Drugs 0.000 claims 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims 4
- 239000000612 proton pump inhibitor Substances 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 claims 4
- 229960000491 rocuronium Drugs 0.000 claims 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 4
- 229960002646 scopolamine Drugs 0.000 claims 4
- 229960001940 sulfasalazine Drugs 0.000 claims 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 4
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims 4
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 claims 4
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 claims 4
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims 4
- 229960001844 tubocurarine Drugs 0.000 claims 4
- 229960001722 verapamil Drugs 0.000 claims 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 3
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 3
- 108010016076 Octreotide Proteins 0.000 claims 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 3
- 229940015042 glycopyrrolate Drugs 0.000 claims 3
- 239000002395 mineralocorticoid Substances 0.000 claims 3
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 claims 3
- 229940072272 sandostatin Drugs 0.000 claims 3
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 claims 3
- 229940032712 succinylcholine Drugs 0.000 claims 3
- CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 claims 3
- 229940035742 trimethaphan Drugs 0.000 claims 3
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 229960002525 mecamylamine Drugs 0.000 description 8
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 201000000117 functional diarrhea Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010000059 abdominal discomfort Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960001263 mecamylamine hydrochloride Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000008559 autonomic dysreflexia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000000181 nicotinic agonist Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008752 Choreiform movements Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010059158 Infrequent bowel movements Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 229940123925 Nicotinic receptor agonist Drugs 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940087211 ciprofloxacin and metronidazole Drugs 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 201000000255 cycloplegia Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- JOPQZCZKKFHRNT-UHFFFAOYSA-N heptan-2-amine;hydrochloride Chemical compound Cl.CCCCCC(C)N JOPQZCZKKFHRNT-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 239000003367 nicotinic antagonist Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45452703P | 2003-03-14 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200507159B true ZA200507159B (en) | 2008-03-26 |
Family
ID=32990912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200507159A ZA200507159B (en) | 2003-03-14 | 2005-09-06 | Treatment of intestinal conditions with N-2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040209961A1 (pt) |
| EP (1) | EP1603544B1 (pt) |
| JP (1) | JP2006520379A (pt) |
| AT (1) | ATE375152T1 (pt) |
| AU (1) | AU2004218899A1 (pt) |
| CA (1) | CA2518385A1 (pt) |
| CY (1) | CY1108042T1 (pt) |
| DE (1) | DE602004009414T2 (pt) |
| DK (1) | DK1603544T3 (pt) |
| ES (1) | ES2294480T3 (pt) |
| MX (1) | MXPA05009640A (pt) |
| NO (1) | NO20054670L (pt) |
| NZ (1) | NZ542260A (pt) |
| PL (1) | PL1603544T3 (pt) |
| PT (1) | PT1603544E (pt) |
| WO (1) | WO2004080446A1 (pt) |
| ZA (1) | ZA200507159B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| US20060182819A1 (en) * | 2005-02-17 | 2006-08-17 | Ough Yon D | Soap scent patch and treatment for muscle spasm and pain |
| US20060182818A1 (en) * | 2005-02-17 | 2006-08-17 | Ough Yon D | Transdermal patch and treatment for pain and discomfort |
| US20070108228A1 (en) * | 2005-11-15 | 2007-05-17 | Willam Kleyne | Method and apparatus for flushing eyes and skin |
| US20080207766A1 (en) * | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
| EP3061449A1 (en) * | 2009-09-29 | 2016-08-31 | Novartis AG | Dosage regimen of an s1p receptor modulator |
| US8529914B2 (en) | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| EP3439676B1 (en) | 2016-04-04 | 2021-06-09 | Omeza LLC | Fish oil topical composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034079A (en) * | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| AU750808B2 (en) * | 1997-10-03 | 2002-07-25 | Cary Medical Corporation | Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
| AR016212A1 (es) * | 1998-04-28 | 2001-06-20 | Astra Ab | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas |
| US6121289A (en) * | 1998-10-09 | 2000-09-19 | Theramax, Inc. | Method for enhanced brain delivery of nicotinic antagonist |
| NZ512788A (en) * | 1998-12-07 | 2003-07-25 | Elan Corp Plc | Transdermal patch for delivering volatile liquid drugs |
| EP1139743B1 (en) * | 1998-12-16 | 2006-03-22 | University Of South Florida | Exo-s-mecamylamine formulation and use in treatment |
| US6734215B2 (en) * | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| WO2001052823A2 (en) * | 2000-01-20 | 2001-07-26 | Noven Pharmaceuticals, Inc. | Compositions to effect the release profile in the transdermal administration of drugs |
| US6780871B2 (en) * | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
-
2004
- 2004-03-12 PT PT04720110T patent/PT1603544E/pt unknown
- 2004-03-12 CA CA002518385A patent/CA2518385A1/en not_active Abandoned
- 2004-03-12 MX MXPA05009640A patent/MXPA05009640A/es active IP Right Grant
- 2004-03-12 AU AU2004218899A patent/AU2004218899A1/en not_active Abandoned
- 2004-03-12 DE DE602004009414T patent/DE602004009414T2/de not_active Expired - Lifetime
- 2004-03-12 DK DK04720110T patent/DK1603544T3/da active
- 2004-03-12 PL PL04720110T patent/PL1603544T3/pl unknown
- 2004-03-12 JP JP2006506469A patent/JP2006520379A/ja active Pending
- 2004-03-12 US US10/798,421 patent/US20040209961A1/en not_active Abandoned
- 2004-03-12 EP EP04720110A patent/EP1603544B1/en not_active Expired - Lifetime
- 2004-03-12 AT AT04720110T patent/ATE375152T1/de not_active IP Right Cessation
- 2004-03-12 WO PCT/IB2004/001134 patent/WO2004080446A1/en active Search and Examination
- 2004-03-12 ES ES04720110T patent/ES2294480T3/es not_active Expired - Lifetime
- 2004-03-12 NZ NZ542260A patent/NZ542260A/xx unknown
-
2005
- 2005-09-06 ZA ZA200507159A patent/ZA200507159B/en unknown
- 2005-10-11 NO NO20054670A patent/NO20054670L/no not_active Application Discontinuation
-
2008
- 2008-01-09 CY CY20081100029T patent/CY1108042T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1603544T3 (da) | 2008-01-14 |
| NO20054670D0 (no) | 2005-10-11 |
| ATE375152T1 (de) | 2007-10-15 |
| WO2004080446A1 (en) | 2004-09-23 |
| EP1603544B1 (en) | 2007-10-10 |
| PL1603544T3 (pl) | 2008-03-31 |
| WO2004080446B1 (en) | 2004-12-09 |
| DE602004009414T2 (de) | 2008-07-24 |
| ES2294480T3 (es) | 2008-04-01 |
| NO20054670L (no) | 2005-12-13 |
| DE602004009414D1 (de) | 2007-11-22 |
| EP1603544A1 (en) | 2005-12-14 |
| PT1603544E (pt) | 2008-01-22 |
| JP2006520379A (ja) | 2006-09-07 |
| US20040209961A1 (en) | 2004-10-21 |
| MXPA05009640A (es) | 2005-10-26 |
| NZ542260A (en) | 2009-03-31 |
| CA2518385A1 (en) | 2004-09-23 |
| AU2004218899A1 (en) | 2004-09-23 |
| CY1108042T1 (el) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200507159B (en) | Treatment of intestinal conditions with N-2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine | |
| Biederman et al. | Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD | |
| Adler et al. | Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis | |
| Montorsi et al. | Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies | |
| Fava et al. | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. | |
| Ellis et al. | Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria | |
| Blomqvist et al. | Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol | |
| Moore et al. | Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate | |
| Grubb et al. | Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension | |
| JP2003515564A (ja) | Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物 | |
| Lipman | Analgesic drugs for neuropathic and sympathetically maintained pain | |
| Waters et al. | Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension-results of the TOPIC (Trial Of Physiotens In Combination) Study | |
| US20230338367A1 (en) | Treatment of prurigo nodularis | |
| Delles et al. | Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension | |
| Lubin et al. | Short‐term treatment of post‐traumatic stress disorder with naltrexone: An open‐label preliminary study | |
| US11166922B2 (en) | Method for treating hyperhidrosis with dexmecamylamine | |
| Klein et al. | A double‐blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension | |
| AU2019301134A1 (en) | Treatment of the pruritic symptoms of liver disease | |
| US20220265640A1 (en) | Methods of administering nalbuphine | |
| Violante-Ortíz et al. | Use of sibutramine in obese Hispanic adolescents | |
| US20230000796A1 (en) | Intranasal administration of ketamine to cluster headache patients | |
| Levine | Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension | |
| Sanjuliani et al. | Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients | |
| WO2021177257A1 (ja) | 原発性腋窩多汗症の治療方法、及びその医薬 | |
| Bioulac et al. | Stimulants |